Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2024年5月3日 - 11:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: May 3, 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
EXHIBIT INDEX
|
Exhibit
No.
|
Description
of Exhibit
|
|
99.1
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: May 3,
2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
May 3, 2024
Indivior PLC (the 'Company')
Publication of Circular and Notice of General Meeting
On April 25, 2024, the Board of Directors of the Company confirmed
its intention, following extensive consultation with shareholders,
to seek shareholder approval in May 2024 to effect a primary
listing in the U.S., while maintaining a secondary listing in the
U.K.. In order to effect a primary listing in the U.S., shareholder
approval is being sought to transfer the Company's listing category
on the Official List of the U.K. Financial Conduct Authority
("FCA") from a Premium Listing (commercial company) to
a Standard Listing (shares) (the "Proposed
Transfer").
Further to that announcement, the Company has today posted or made
available to shareholders a circular (the "Circular") incorporating a notice of general meeting (the
"General
Meeting") regarding the
Proposed Transfer.
Copies of the following documents have been submitted to the FCA
and will shortly be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism:
− Circular incorporating the notice of General
Meeting; and
− Form of Proxy for the General
Meeting.
The Circular incorporating the notice of General Meeting can also
be viewed on the Company's website at www.indivior.com/en/investors/shareholder-information and
will be available for inspection at
the place of the General Meeting for at least 15 minutes before and
during the General Meeting.
The General Meeting will be held on Thursday, May 23, 2024, at
12.00 p.m. (U.K. time) at the offices of Freshfields Bruckhaus
Deringer LLP, 100 Bishopsgate, London EC2P
2SR.
The expected timetable for the General Meeting and the Proposed
Transfer is set out below. All times shown in this timetable are
U.K. time.
|
Event
|
|
Expected time/date
|
|
Record
date for DTC beneficial owners to be eligible to vote
|
|
Friday,
May 10, 2024
|
|
Latest
time and date for receipt of Forms of Direction(U.K. CSN
holders)
|
|
12.00p.m. on Friday,
May 17, 2024
|
|
Record
date for CSN holders to be eligible to vote
|
|
6.00p.m.
onFriday, May 17, 2024
|
|
Record
date for U.K. Depositary Interest holders to be eligible to
vote
|
|
6.00p.m.
on Friday, May 17, 2024
|
|
Latest
time and date for receipt of Forms of Instruction(U.K. Depositary
Interest holders)
|
|
12.00p.m. on Monday,
May 20, 2024
|
|
Latest
time and date for receipt of Forms of Proxy(direct
shareholders)
|
|
12.00p.m.
onTuesday, May 21, 2024
|
|
Record
date for direct shareholders to attend and voteat the General
Meeting
|
|
12.00p.m.
on Tuesday, May 21, 2024
|
|
General
Meeting
|
|
12.00p.m.
on Thursday, May 23, 2024
|
|
Proposed
Transfer becomes effective and trading of Indivior Shares commences
as a Standard Listing company
|
|
8.00a.m.
onThursday, June 27, 2024
|
All dates are based on Indivior's current expectations and may be
subject to change. If any of the times or dates change, Indivior
will give notice of the change by issuing an announcement through a
Regulatory Information Service.
Capitalised terms used but not otherwise defined in this
announcement have the same meaning given to them in the
Circular.
Key
Contacts:
Jason Thompson
VP, Investor Relations
+1 804-402-7123 or jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
+1 804-263-3978 or timothy.owens@indivior.com
Kathryn Hudson
Company Secretary
+44 (0)1753 423940 or kathryn.hudson@indivior.com
Indivior PLC's Legal Entity Identifier code is
213800V3NCQTY7IED471.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD) and serious mental illnesses. Our vision is that
all patients around the world will have access to evidence-based
treatment for the chronic conditions and co-occurring disorders of
SUD. Indivior is dedicated to transforming SUD from a global human
crisis to a recognized and treated chronic disease. Building on its
global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this
category and potentially address other chronic conditions and
co-occurring disorders of SUD, including alcohol use disorder and
cannabis use disorder. Headquartered in the United States in
Richmond, VA, Indivior employs over 1,100 individuals globally and
its portfolio of products is available in 37 countries worldwide.
Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/
company/indivior.
Indivior (PK) (USOTC:IZQVF)
過去 株価チャート
から 4 2024 まで 5 2024
Indivior (PK) (USOTC:IZQVF)
過去 株価チャート
から 5 2023 まで 5 2024
